Back to overview

Phenylbenzenesulfonates and -sulfonamides as 17β-hydroxysteroid dehydrogenase type 2 inhibitors: Synthesis and SAR-analysis

Type of publication Peer-reviewed
Publikationsform Original article (peer-reviewed)
Author Vuorinen Anna, Engeli Roger T., Leugger Susanne, Kreutz Christoph R., Schuster Daniela, Odermatt Alex, Matuszczak Barbara,
Project Impact of the NADPH pool in the endoplasmic reticulum on metabolic and hormonal regulation
Show all

Original article (peer-reviewed)

Journal Bioorganic and Medicinal Chemistry Letters
Volume (Issue) 27(13)
Page(s) 2982 - 2985
Title of proceedings Bioorganic and Medicinal Chemistry Letters
DOI 10.1016/j.bmcl.2017.05.005


© 2017 Elsevier Ltd 17β-Hydroxysteroid dehydrogenase type 2 (17β-HSD2) converts the potent estrogen estradiol into the weakly active keto form estrone. Because of its expression in bone, inhibition of 17β-HSD2 provides an attractive strategy for the treatment of osteoporosis, a condition that is often caused by a decrease of the active sex steroids. Currently, there are no drugs on the market targeting 17β-HSD2, but in multiple studies, synthesis and biological evaluation of promising 17β-HSD2 inhibitors have been reported. Our previous work led to the identification of phenylbenzenesulfonamides and -sulfonates as new 17β-HSD2 inhibitors by ligand-based pharmacophore modeling and virtual screening. In this study, new molecules representing this scaffold were synthesized and tested in vitro for their 17β-HSD2 activity to derive more profound structure-activity relationship rules.